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Summary.-Twenty-seven patients with malignant neoplasia were injected intra-
dermally with the methanol extraction residue (MER) fraction of tubercle bacilli.
Two schedules of treatment were used: every other week and once a month; 1-10
courses of MER were administered to the patients. The skin reactivity to 3 recall
antigens, as well as to the injected MER itself, was used to monitor the immune
response. Improvement of skin reactivity occurred in 9 of 18 patients tested with
recall antigens. Five of 6 patients treated every other week improved in their
immune capacity whereas only 4 of 12 patients improved on the monthly schedule.
Thus, repeated injections given every other week were more effective in increasing
the cutaneous reactivity than monthly injections of MER. The side-effects of MER
treatment were tolerable.
THE SUCCESSFUL use of BCG (bacillus
Calmette-Guerin) in the treatment of
animals and humans bearing tumours
has been reported (Old, Clarke and
Benacerraf, 1959; Mathe et al., 1969;
Bast et al., 1974). MER is a methanol
extraction residue of BCG; it is not
viable and has a broad activity as a
stimulant of immunological reactivity
and of resistance to microbial pathogens
and neoplastic cells (Weiss and Dubos,
1955; Weiss, Bonhag and Leslie, 1966;
Weiss, 1972; Robinson et al., 1972).
Previously, we havereported in tumour
bearing mice thatradiotherapyand chemo-
therapy combined with MER treat-
ment tend to be more effective in reducing
tumour volume and prolonging the sur-
vival of the animals than radio- or
chemotherapy alone (Yron et al., 1973).
In the present study of inoperable cancer
patients, we have evaluated the tolerance
to MER, its effect on the disease and the
skin reactivity to recall antigens.
MATERIALS AND METHODS
Patients.-Twenty-seven patients with
histologically confirmed malignant neoplasia
were included in this study; Table I shows
the diagnoses. Twenty-one of the patients
suffered from inoperable advanced epithelial
cancer and 6 with malignant melanoma;
all melanoma patients underwent resection of
the primary and metastatic regional lymph
nodes and had no evidence of disease. All
the patients except one had a life expectancy
of more than 3 months. The patients were
examined at least every 2 weeks and received
conventional treatment, radio- and/or chemo-
therapy according to standard protocols used
in our department. The informed consent
of the patients was obtained before admission
to the study.
Test antigens. Eighteen patients were
skin tested by intradermal injection of
0-1 ml of 3 recall antigen preparations.
The antigens were purified protein derivative
(Ministry of Health, Israel, 2TU), strepto-
kinase, streptodornase (Lederle, U.S.A., 40 ,u/
10 u), and candida (Institute of Biology,
Nes Ziona, Israel, 0-1%). The skin tests
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TABLE I.-Diagnosis ofPatients
Type of tumour No. of patients
TABLE II.-The Skin Reactivity to
Intradermal Injections of MER
Melanoma 6
Lung carcinoma 7
Bladder carcinoma 3
Colon carcinoma 3
Larynx carcinoma 2
Other carcinomata: 6
(breast, ovary, retroperitoneal
tu., oesophagus, pancreas,
tongue)
Total 27
were performed simultaneously on the fore-
arm of the patients and were repeated
monthly. The average diameter of indura-
tion at 48 h was recorded in mm. A negative
reaction was defined as an induration of
0-3 mm, a weak reaction 4-8 mm and a
strong reaction >8 mm. Immunoincom-
petence was defined as no response to 2
recall antigens (hypoergy) or to all 3 antigens
(anergy).
MER.-MER (from a batch made by
Merck, Sharpe and Dohme, New Jersey,
U.S.A.) was given intradermally on the
back by 10 injections each containing 0-1 mg
for a total of 1I0 mg per patient. Two
schedules of treatment were used. Twelve
patients were given MER once a month
(Schedule A) and 11 patients every other
week (Schedule B). A total of 99 treatments
of MER were given. Twenty patients re-
ceived 3-10 courses of MER, 3 received
2 courses only and 4 had only one course.
Skin reactivity to MER was recorded a
week after each course of injections. On
each examination previous sites of MER
injections were evaluated. The intensity
of the skin reaction to MER was graded
according to average diameter of induration
obtained by 2 rightangle measurements: no
response, weak response (induration of up
to 3 mm), medium response (induration
of 4-10 mm) and strong response (10 mm
or more of induration with caseation and
ulceratiotn).
RESULTS
The strength of the reaction at the
MER injection site in the patients is
shown in Table II. It can be seen that
at the first administration of MER, 11
patients had a weak, 13 a medium and
only 3 a strong reaction.
Weak
No. of Strong Medium or no
patients reaction reaction response
27 3 13 11
20 10 7 3
No. of
MER
courses
1
>3
After 3 or more courses of MER, the
reaction was found to be strong in 10
patients, medium in 7 and weak in 3
(a change from weak to medium or to
strong from medium).
MER induced in most patients a
local inflammatory reaction which some-
times progressed to necrosis, ulceration
and squama formation.
The injection sites usually became
slightly painful and rarely secreted vari-
able amounts of caseous material. After
repeated injections of MER, a typical
flare up phenomenon of the previous
sites of injection was observed. All
lesions resolved in a period of 3-6 weeks.
In 3 of the 27 patients, regional
lymph nodes became palpable and tender
with repeated injections and regressed
spontaneously after 6 weeks. Four pa-
tients had fever up to 39°C with malaise
that lasted 24-72 h after injection. One
patient with lung cancer had a general
eruption, appearing 10 days after the
second course of MER with a rash
resembling the reaction in the MER
injection sites. This patient was known
to suffer from rheumatic fever and other
allergic reactions.
Liver function tests including albumin,
globulin, alkaline phosphatase, cephalin,
thymol, transaminase, were normal in all
patients.
Table III depicts the skin reactivity
of 18 patients to the 3 recall antigens.
Before treatment, 7 patients were anergic
or hypoergic and 11 patients reacted
normally. After MER immunization,
none remained anergic, 4 patients were
hypoergic and 14 reacted normally. As
awhole, an improvement in skin reactivity
to recall antigens occurred in 9 of the
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TABLE III.-The Skin Reactivity to
Recall Antigens in 18 Patients
Skin reactivity
Negative 3 antigens
Negative-2 antigens
l'ositive all 3 antigenis
Positive 2 antigenis
Pre-
treatmeiit
(18 patients)
3\\7
4/
8,
Post AIER
treatment
(18 patients)
0\ 4
4/
11
>11
3
>14
18 patients. Five of these 9 patients
received treatment every other week and
4 once a month (Table IV). Both groups
of patients received 3-6 courses of MER,
except one patient in Schedule B who
received 10 courses of MER.
Of the 27 patients, 5 patients died
from their tumour during the course
of the study; 4 of these received 1-2
courses of MER and one received 4
courses. The other 22 patients are still
living more than 6 months after diagnosis.
All these patients except one showed no
progression in their disease. The latter
is a patient with malignant melanoma
who, during a local recurrence, received
his first treatment of MER. Though
he received a further course of immuno-
therapy, his disease progressed but all
his skin tests remained positive.
It is worth noting that the 4 patients
(Table IV) whose skin reactivity deterior-
ated in spite of MER treatment are still
without evidence of progression in their
disease.
TABLE IV.-The Skin Test Reactivity
after MER Treatment
Sche(lule
Monthly
Every other
week
Skin reactivitv
No. of Improve- No Deterio-
patients ment change ration
12 4 5 3
6 5 0 1
IDISCUSSION
Immunotherapy has been given to
many cancer patients with living BCG.
Some investigators have reported im-
provement (Mathe et al., 1969; Morton et
al., 1970; Gutterman et al., 1974), but
serious side-effects to this treatment have
also been described (Sparks et al., 1973;
Hunt, Silverstein and Sparks, 1973). In
contrast, the MER fraction of BCG has
the advantage over the living organism
of being a non-viable material. In mice,
it has been proved to have considerable
therapeutic efficacy and no side-effects
(Yron et al., 1973).
In the present work, we have shown
that MER can be given every other
week or once a month with no serious
complications. Patients who were anergic
to a battery of skin tests had a low or
no local reaction to the MER injection.
In 9 patients the skin reactivity became
stronger during treatment. This occurred
more often in patients treated every
other week (5 of 6 patients) than in
patients treated with MER once a month
(4 of 12). Because of the local reactions,
MER immunotherapy should not be
given more frequently.
The danger that overstimulation of
the immune response would enhaince
tumour growth (Baldwin and Pimm,
1973a, b; Piessens et al., 1970, 1971)
should also be taken into consideration
when the number and schedules of treat-
ment are decided.
It is apparent that MER has no
serious deleterious side-effects in man
and is well tolerated by the patients.
As to the one case where a skin eruption
developed, it must be noted that similar
phenomena have been observed with
BCG treatment (Hersh, personal com-
munication).
Further trials in patients with no
evidence of gross disease, but known
to have poor prognosis, should now be
undertaken.
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